We are enclosing herewith the following: a. Audited Financial Results for the Financial Year ended March 31, 2026, as per format prescribed under Regulation 33 of Securities Exchange Board ....
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Procter & Gamble Health Ltd reported strong full-year results for FY 2025-26 (12 months). Revenue from operations grew to ₹1,40,797 lakhs and net profit reached ₹32,691 lakhs, compared to the prior 9-month period (FY 2024-25) which had revenue of ₹93,417 lakhs and PAT of ₹23,441 lakhs. EPS for the year stood at ₹196.94 per share. The company also received an unmodified (clean) audit opinion from Haribhakti & Co. LLP. The Board recommended a final dividend of ₹45 per equity share, which together with an interim dividend of ₹160 per share makes the total dividend ₹205 per share for FY 2025-26. Note: The company changed its financial year from June to March, making the previous year's figures for only 9 months.
Positive signals for shareholders: strong profit growth, clean audit, and robust dividend payout. The change in financial year-end means direct year-on-year comparison requires adjustment for the 9-month vs 12-month period difference.